ArticleThe British journal of radiology2025
MRI-based radiomics nomogram to predict complete response to definitive chemoradiation in patients with anal cancer.
Article in The British journal of radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectivesTreatment response to definitive chemoradiation (dCRT) in patients with anal cancer varies significantly, with a subset experiencing persistent or progressive disease despite therapy. Radiomics extracts quantitative features from radiological images, with the potential to develop predictive tools to assess treatment response. We aim to develop and validate an MRI-based radiomics nomogram to predict response to dCRT in patients with anal cancer.
methodsA single-institutional retrospective analysis of 45 patients with anal cancer treated with dCRT was performed. Radiomic features were extracted from pre-treatment T2-weighted MRI scans, and predictive models were constructed. Clinical and radiomic features were analysed to develop the nomogram. Internal validation with 1000 bootstrap samples was performed to calculate optimism-corrected performance measures.
resultsOverall, 30/45(66.7%) achieved a complete treatment response. Male gender was found to be an independent predictor of incomplete response to dCRT (OR 4.763,95% CI: 1.170-19.384,*P = .029). Two radiomic signatures emerged as strong predictors of treatment response to dCRT. The combined model outperformed the clinical and radiomic models. The combined model showed the highest predictive accuracy, achieving an apparent area under the receiver operating characteristic curve (AUC): 0.87 (0.75-0.99) and an optimism-corrected AUC: 0.85, mean absolute error: 0.029, positive predictive value (0.68) and negative predictive value (0.92), indicating excellent discriminative performance. It demonstrated a positive net benefit in decision analysis. The optimism-corrected calibration curves demonstrate that the radiomic and combined model provide well-calibrated predictions.
conclusionThis MRI-based radiomics nomogram offers a promising approach to predict response to dCRT in patients with anal cancer. ADVANCES IN KNOWLEDGE: This study is the first to integrate radiomics and clinical features into a validated predictive model for anal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.